Cartesian Therapeutics
RNAC | NASDAQ
$6.08
-$0.27 (-4.25%)
At close: Nov 16, 2026, 4:00 PM ET
$6.19
+$0.11 (+1.81%)
After-hours:
Nov 16, 2026, 7:32 PM ET
-4.25%
(1D)No price chart data available for 1D timeframe.
Rating
43
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #446/1021 (Top 44%)
Key Statistics
Market Data
Market Cap $185.46M
1D Range
6.06 6.44
52W Range
5.84 10.59
Valuation (TTM)
PE -1.26
PB -1.42
EV/EBITDA -1.00
Valuation (NTM)
Forward PE N/A
Forward PEG 0.18
Price Target $20.50
Cash Flow
FCF Yield -48.2%
SBC Adj. FCF Yield -51.8%
SBC Impact -7.4%
Margins
Gross Margin 100.0%
Operating Margin -7570.1%
FCF Margin -8725.6%
Growth (CAGR)
Revenue 3Y | 5Y -69.0% |
-56.7%
Dil EPS 3Y | 5Y 121.5% |
-21.4%
FCF 3Y | 5Y -29.8% |
-17.1%
Returns
ROA -44.0%
ROE 97.7%
ROIC -33.8%
Financial Health
Net Cash
$68.55M
Current Ratio 8.38
Interest Coverage -36.09
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an au...
Sector Healthcare
Industry Biotechnology
Employees 75
IPO Date Jun 22, 2016
Website cartesiantherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.38
Beat +62.38%
YoY:
+72.46% REV
$250K
Beat +56.25%
YoY:
-44.69%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$20.50
Upside
+237.17%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RNAC